Quarterly ResultMay 14, 2026, 04:23 PM
VolitionRx Q1 2026 Revenue $1.0M; Advances Nu.Q® Pipeline
AI Summary
VolitionRx Limited announced its first quarter 2026 financial results, reporting approximately $1.0 million in revenue, a significant increase from $0.2 million in Q1 2025, and a 3% reduction in operating loss. The company made strong progress across its product pillars, including submitting its Nu.Q® Vet feline assay for peer review, which is expected to unlock a $5 million milestone payment. VolitionRx is also advancing reimbursement for Nu.Q® Lung Cancer and exploring new clinical applications for its Nu.Q® NETs assay, while actively pursuing licensing agreements with diagnostic companies.
Key Highlights
- Q1 2026 revenue was approximately $1.0 million, up from $0.2 million in Q1 2025.
- Operating loss decreased by 3% compared to the prior year quarter.
- Net cash used in operating activities totaled $5.3 million.
- Secured $5.4 million from equity sales and $1.9 million from convertible note.
- Submitted Nu.Q® Vet feline assay for peer review, expecting a $5 million milestone.
- Advanced reimbursement submission for Nu.Q® Lung Cancer in Europe.
- Identified new clinical use cases for Nu.Q® NETs in trauma and Hidradenitis Suppurativa.
- Engaged in licensing discussions with over a dozen diagnostic companies.